These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 641713

  • 1. Pharmacokinetics of Aryldihydro-s-triazines with antifolate activity II: Blood levels and their relevance to antineoplastic activity in rats.
    Upton RA, Ashley JJ, Ryan AJ.
    J Pharm Sci; 1978 Mar; 67(3):310-4. PubMed ID: 641713
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Quantitative structure-activity relationships of the inhibition of Pneumocystis carinii dihydrofolate reductase by 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(X-phenyl)-s-triazines.
    Marlowe CK, Selassie CD, Santi DV.
    J Med Chem; 1995 Mar 17; 38(6):967-72. PubMed ID: 7699713
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of dihydrofolate reductase. 3. 4.6-Diamino-1,2-dihydro-2,2-dimethyl-1-(2-substituted-phenyl)-s-triazine inhibition of bovine liver and mouse tumor enzymes.
    Kim KH, Dietrich SW, Hansch C, Dolnick BJ, Bertino JR.
    J Med Chem; 1980 Nov 17; 23(11):1248-51. PubMed ID: 7452676
    [Abstract] [Full Text] [Related]

  • 7. Irreversible enzyme inhibitors. CLXXVII. Active-site-directed irreversible inhibitors of dihydrofolate reductase derived from 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(phenylalkylphenyl)-s-triazines. II.
    Baker BR, Vermeulen NM.
    J Med Chem; 1970 Nov 17; 13(6):1154-60. PubMed ID: 5479856
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Irreversible enzyme inhibitors. CLXXIV. Metabolism of 4-(p-(4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazin-1-yl)hydrocinnamido)-o-toluenesulfonyl fluoride (NSC-113423), an active-site-directed irreversible inhibitor of dihydrofolic reductase.
    Ryan AJ, Vermeulen NM, Baker BR.
    J Med Chem; 1970 Nov 17; 13(6):1140-2. PubMed ID: 5479853
    [No Abstract] [Full Text] [Related]

  • 11. Inhibition of bovine and rat liver dihydrofolate reductase by 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(4-substituted-phenyl)-s-triazines.
    Hansch C, Dietrich SW, Fukunaga JY.
    J Med Chem; 1981 May 17; 24(5):544-9. PubMed ID: 7241512
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Irreversible enzyme inhibitors. 178. Active-site-directed irreversible inhibitors of dihydrofolate reductase derived from 1-(4-benzyloxy-3-chlorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazine with a terminal sulfonyl fluoride.
    Baker BR, Ashton WT.
    J Med Chem; 1970 Nov 17; 13(6):1161-5. PubMed ID: 5479857
    [No Abstract] [Full Text] [Related]

  • 14. Ligand binding studies, preliminary structure-activity relationship and detailed mechanistic characterization of 1-phenyl-6,6-dimethyl-1,3,5-triazine-2,4-diamine derivatives as inhibitors of Escherichia coli dihydrofolate reductase.
    Srinivasan B, Tonddast-Navaei S, Skolnick J.
    Eur J Med Chem; 2015 Oct 20; 103():600-14. PubMed ID: 26414808
    [Abstract] [Full Text] [Related]

  • 15. Irreversible enzyme inhibitors. 196. Active-site-directed irreversible inhibitors of dihydrofolate reductase derived from 1-(4-benzyloxy-3-chlorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazine and bearing a terminal phenyl sulfonate group.
    Baker BR, Ashton WT.
    J Med Chem; 1972 Sep 20; 15(9):945-7. PubMed ID: 5051014
    [No Abstract] [Full Text] [Related]

  • 16. Quantitative structure-activity relationship of triazine-antifolate inhibition of Leishmania dihydrofolate reductase and cell growth.
    Booth RG, Selassie CD, Hansch C, Santi DV.
    J Med Chem; 1987 Jul 20; 30(7):1218-24. PubMed ID: 3599028
    [Abstract] [Full Text] [Related]

  • 17. Comparison of triazines as inhibitors of L1210 dihydrofolate reductase and of L1210 cells sensitive and resistant to methotrexate.
    Selassie CD, Strong CD, Hansch C, Delcamp TJ, Freisheim JH, Khwaja TA.
    Cancer Res; 1986 Feb 20; 46(2):744-56. PubMed ID: 3940640
    [Abstract] [Full Text] [Related]

  • 18. A comparison of the inhibition of bovine and murine leukemia dihydrofolate reductase by 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(3-X-phenyl)-s-triazines.
    Guo ZR, Dietrich SW, Hansch C, Dolnick BJ, Bertino JR.
    Mol Pharmacol; 1981 Nov 20; 20(3):649-56. PubMed ID: 7329407
    [No Abstract] [Full Text] [Related]

  • 19. Irreversible enzyme inhibitors. 108. p-(4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazin-1-yl)phenylpropionylsulfanilyl fluoride, an active-site-directed irreversible inhibitor of dihydrofolic reductase. IV. Effects of substitution on the propionamide bridge on isozyme specificity.
    Baker BR, Lourens GJ.
    J Med Chem; 1968 Jul 20; 11(4):672-7. PubMed ID: 5244345
    [No Abstract] [Full Text] [Related]

  • 20. Irreversible enzyme inhibitors. CXXVII. p-(2,6-diamino-1,2-dihydro--2,2-dimethyl-s-triazin-1-yl)phenylpropionylsulfanilyl fluoride, an active-site-directed irreversible inhibitor of dihydrofolic reductase. 3. Effects of modification of the propionamide bridge on isozyme specificity.
    Baker BR, Luorens GJ.
    J Med Chem; 1968 Jul 20; 11(4):666-72. PubMed ID: 5244344
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.